Torzilli Guido
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Division of Hepatobiliary & General Surgery, Department of Surgery - IRCCS, Humanitas Research Hospital, Milan, Italy.
Glob Health Med. 2023 Aug 31;5(4):246-248. doi: 10.35772/ghm.2023.01020.
Sorafenib is a breakthrough in the medical treatment aiming to control hepatocellular carcinoma (HCC) progression, but there is some controversy in patients' selection. The introduction of Sorafenib has led to several positive effects. New more than promising antiangiogenic molecules have followed. Immunotherapy combined with antiangiogenic therapy has also strongly entered into the treatment of HCC. All of that has induced a significant guideline revision profiling Sorafenib as a second line systemic therapy in the event of advanced HCC. However, for those patients with advanced but resectable HCC, the selection of surgery or systemic therapy should be reviewed and reconsidered.
索拉非尼是旨在控制肝细胞癌（HCC）进展的医学治疗方面的一项突破，但在患者选择上存在一些争议。索拉非尼的引入带来了若干积极影响。随后出现了更多有前景的抗血管生成分子。免疫疗法联合抗血管生成疗法也强势进入HCC治疗领域。所有这些都促使对相关指南进行了重大修订，将索拉非尼作为晚期HCC的二线全身治疗方案。然而，对于那些晚期但可切除的HCC患者，手术或全身治疗的选择应重新审视和考量。
